Santhera Pharmaceuticals announced significant results from the LIONHEART study back in 2024, pushing the boundaries on AGAMREE® (vamorolone) and its role as a game changer for treating Duchenne muscular dystrophy (DMD). This ain’t just another run-of-the-mill clinical trial; it shines a spotlight on vamorolone’s unique position as a mineralocorticoid receptor antagonist, setting it apart from conventional corticosteroids that have dominated the scene. Traders were buzzing—could this be the new standard for DMD care?
Santhera Reports Breakthrough LIONHEART Study Findings